Mandate

Vinge advises Embellence Group AB (publ) in connection with the listing on Nasdaq First North Premier Growth Market

Vinge advises Embellence Group AB (publ) (“Embellence Group”) in connection with the listing on Nasdaq First North Premier Growth Market. The offering circular was published on 15 March 2021 and first day of trading was on 24 March 2021.

The offering price was SEK 42, corresponding to a market value of Embellence Group of approximately SEK 900 million. The offering comprised approximately 10.8 million shares, corresponding to a value of approximately SEK 454 million, provided that the overallotment option is exercised in its entirety.

Embellence Group, founded in 1905 in Borås, Sweden, is a leding European company in interior decoration, with a focus on premium brands within wallpaper, textile, rugs and other interior decoration with sales in over 90 countries. The company’s brand portfolio includes Cole & Son, Wall&decò, Perswall, Pappelina and Boråstapeter.

Vinge’s team mainly consisted of Johan Winnerblad, Jesper Schönbeck, Rikard Lindahl, Joel Magnusson, Linnea Petersson and Louise Brorsson Salomon, Pauline Lagerstrand and Rebecka Målquist regarding financing matters and Mattias Schömer and Henrik Wastenson regarding tax matters.

 

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025